About Mynvax
Mynvax is a Healthcare company based in Bengaluru (India) founded in 2017. Novel recombinant vaccines against influenza and COVID-19 are developed. Mynvax has raised $9.82 million across 5 funding rounds from investors including Kotak Mahindra Bank, Accel and LetsVenture. The company has 26 employees. Mynvax was last valued at $17.63 million in July 2021. Its Indian entity Mynvax Private Limited reported revenue of ₹3.56 Cr. Mynvax offers products and services including Influenza Vaccine and COVID-19 Vaccine. Its focus areas include Life Sciences, Infectious Diseases, Drugs and Viral.
Company details
Mynvax was established in 2017 in Bengaluru, India, within the biotechnology sector focused on vaccine development. Operations center on creating recombinant vaccines targeting the human influenza virus and SARS-CoV-2. Genetic engineering is applied to the receptor binding domain of the viruss spike glycoprotein, enabling attachment to ACE2 receptors in human respiratory cells. Research and production activities are conducted to address viral threats in this field.
- Headquarters Bengaluru, India
- Employees 26
- Stage Minicorn
- SectorsHealthcare
- Website mynvax.com
- Social LinkedIn
- Legal Name Mynvax Private Limited
- Date of Incorporation 05 May, 2017
- Jurisdiction Bangalore, Karnataka, India
- Annual Revenue₹3.56 Cr
FY 2025 · +26% YoY
- Net Loss-₹22.58 Cr
FY 2025 · -635% margin
- EBITDA-₹21.61 Cr
FY 2025 · -607% margin
- Total Equity Funding$9.82M (USD)
in 5 rounds
- Latest Funding Round$2.6M (USD), Series A
May 2024
- InvestorsKotak Mahindra Bank
& 70 more
- Employee Count26
Associated legal entities of Mynvax
Mynvax operates through Mynvax Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2025) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Mynvax Private Limited CIN U73200KA2017PTC102838 | Active | 05 May 2017 | Bangalore, Karnataka | ₹3.6 Cr | 26 | 7 | View details |
Products & Services of Mynvax
Mynvax offers a comprehensive portfolio of products and services, including Influenza Vaccine and COVID-19 Vaccine.
Thermostable recombinant vaccine for influenza protection.
Efficacious thermotolerant vaccine against COVID-19 variants.
Funding Insights of Mynvax
Mynvax has successfully raised a total of $9.82M across 5 strategic funding rounds. The most recent funding activity was a Series A round of $2.6 million completed in May 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $9.82M
- Total Rounds 5
- Last Round Series A — $2.6M
- First Round $781,354
(Aug 2018)
- Investors Count 71
All 5 funding rounds of Mynvax with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May 2024 | $2.6M | Series A | – | Legacy Assets | |
| Jul 2021 | $4.2M | Series A | $17.63M | Accel, N Lakshmi Narayanan | |
| Aug 2020 | Grant | – | – | ||
| Oct 2019 | $2.24M | Seed | $3.45M | Lakshmi Narayanan, Lakshmi Narayanan | |
| Aug 2018 | $781,354 | Seed | – | Ganesh Kishore, Nadig Advisors |
| Date | Valuation | Stage |
|---|---|---|
| Jul 2021 | $17.63M | •••••••• |
| Oct 2019 | $3.45M | •••••••• |
Last known valuation $17.63M (Jul 2021). 71 investors in total: 13 institutional and 58 angel.
Investors in Mynvax
Mynvax has secured backing from 71 investors, including institutional, venture fund, and angel investors. Prominent investors backing the company include Kotak Mahindra Bank, Accel and LetsVenture.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Accel is recognized as a leading venture capital firm. | 1983 | accel.com | Palo Alto, United States | |
Private equity firm focused on multiple sectors | Bengaluru, India | |||
Venture capital fund focused on healthtech, biotech, and multiple sectors | Mumbai, India | |||
A private equity fund focused on supporting healthcare and pharmaceutical enterprises. | 2022 | inviga.in | Bengaluru, India | |
Online platform that connects startup founders with accredited investors, enabling early-stage fundraising and investment opportunities for private market growth | 2013 | letsventure.com | Bengaluru, India | |
Early-stage venture capital investment firm | 2015 | 1crowd.co | Mumbai, India | |
Commercial banking services are offered to corporate and retail customers. | 1985 | kotak.com | Mumbai, India | |
Supplying steel and energy raw materials through commodity trading, mining, and green investing. | enrsingapore.com | |||
Italica is engaged in manufacturing and selling plastic furniture. | 1992 | italica.com | Mumbai, India | |
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability | 1958 | europa.eu | Brussels, Belgium |
Investor details for Mynvax
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Board of directors of Mynvax Private Limited (Mynvax)
Mynvax Private Limited is the primary company behind Mynvax. The board of Mynvax Private Limited currently have 6 directors; the longest-serving is Gautham Nadig, appointed in 2017. 4 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Gautham Nadig DIN 00004457 | Director | 05 May 2017 | 9 yrs 6 mo | Mynvax Private Limited |
| Raghavan Varadarajan DIN 07791448 | Director | 05 May 2017 | 9 yrs 6 mo | Mynvax Private Limited |
| Ganesh Murthy Kishore DIN 05190746 | Director | 29 Dec 2017 | 8 yrs 10 mo | Mynvax Private Limited |
| Anil Gudibande DIN 03071665 | Director | 16 Oct 2019 | 7 yrs | Mynvax Private Limited |
| Arun Suresh Chandavarkar DIN 01596180 | Director | 01 Jan 2021 | 5 yrs 10 mo | Mynvax Private Limited |
| Mahendran Balachandran DIN 00121640 | Nominee Director | 07 Aug 2021 | 5 yrs 3 mo | Mynvax Private Limited |
Financials of Mynvax
Figures of Mynvax Private Limited, the primary company behind Mynvax, for FY 2025. Revenue was ₹3.56 Cr (+26% year on year). Net loss was -₹22.58 Cr (-635% margin). EBITDA was -₹21.61 Cr (-607% margin). Revenue has grown at a compounded annual rate of -15% over three years and +23% over five years.
- ₹3.56 CrRevenue · FY 2025 · +26% YoY
- -₹22.58 CrNet loss · -635% margin
- -₹21.61 CrEBITDA · -607% margin
- ₹6 LakhPaid-up capital
- 26Employees (provident fund records)
- -15%Revenue CAGR, 3 years
- +23%Revenue CAGR, 5 years
Balance sheet, profit and loss, cash flow and ratios of Mynvax Private Limited are on its company page.
Detailed financial statements for Mynvax
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Mynvax
4 dated milestones of Mynvax across 7 years, from founding to its latest funding, stage changes and deals.
- Founded Mynvax is founded.
- Funding First funding round of $781K.
- Milestone Reaches Minicorn status.
- Funding Latest funding round, Series A, of $2.6M.
Web traffic of Mynvax
The website of Mynvax (mynvax.com) receives about 8K visits a month.
- Monthly visits8K
▲ 575.6% vs previous month
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Mynvax
Complete news archive for Mynvax
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Mynvax
Mynvax was founded in 2017 and raised its 1st funding round 1 year after it was founded.
Mynvax is headquartered in Bengaluru, India. It is registered at Bengaluru, Karnataka, India.
Mynvax is a funded company, having raised a total of $9.82M across 5 funding rounds to date. The company's 1st funding round was a Seed of $781.35K, raised on Aug 2018.
Mynvax has 26 employees.
The primary company behind Mynvax, Mynvax Private Limited, reported revenue of ₹3.56 Cr for FY 2025, up 26% year on year.
Mynvax was established in 2017 in Bengaluru, India, within the biotechnology sector focused on vaccine development. Operations center on creating recombinant vaccines targeting the human influenza virus and SARS-CoV-2. Genetic engineering is applied to the receptor binding domain of the viruss spike glycoprotein, enabling attachment to ACE2 receptors in human respiratory cells. Research and production activities are conducted to address viral threats in this field.
Mynvax offers Influenza Vaccine and COVID-19 Vaccine.
Mynvax has 71 investors. Key investors include Kotak Mahindra Bank, Accel, LetsVenture, Italica, and 1Crowd.
The valuation of Mynvax is $17.63M as of Jul 2021.
Mynvax operates through Mynvax Private Limited.
The legal entities of Mynvax currently have 7 directors, including Hurukadli Chidananda Virupakshappa, Ganesh Murthy Kishore, Gautham Nadig and others.